BET Family Epigenetic Reader Inhibition, Selective Bromodomain Targeting, and High-Purity Reagents for Oncology Development
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BRD3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BRD3 Full-Length / BD1 / BD2 Domain Proteins High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. |
View BRD3 Products |
| Gene Delivery | BRD3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. HEK293 Expressed. |
View BRD3 Products |
| Benchmark Ab | Anti-BRD3 (Clone E3G4Z) Recombinant Sequence verified positive control for IP/Western. |
View BRD3 Products |
| Validator | BRD3 siRNA Set For knockdown verification and specificity controls. |
View BRD3 Products |
| BET Family Sibling | BRD2 High homology bromodomain for selectivity counter-screening |
View BRD2 Products |
| Primary BET Target | BRD4 Primary oncology target for comparative binding studies |
View BRD4 Products |
| Downstream Effector | MYC Transcriptional target for pathway validation studies |
View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| BD1 vs BD2 Domain Selectivity Screening | Isolated BD1 and BD2 domain proteins (>95% purity) with Sequence Verified folding |
| Pan-BET Cross-Reactivity Assessment | Homolog panel (BRD2/BRD3/BRD4/BRDT) strictly verified by mass spec for selectivity assays |
| Cellular Target Engagement Validation | High-concentration stable full-length protein for CETSA correlation studies |
| Compound Binding Affinity Determination | Endotoxin-controlled proteins (<1EU/ug) suitable for SPR/ITC instrumentation |
Live BRD3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BRD3-selective therapeutics is intensifying as the field shifts from pan-BET inhibition (associated with dose-limiting thrombocytopenia) to precise bromodomain targeting. First-generation pan-BET inhibitors demonstrated limited therapeutic windows due to BRD4-related toxicity, driving the next wave of R&D toward BD1-selective versus BD2-selective strategies and heterobifunctional degraders (PROTACs). As NUT carcinoma and MYC-driven solid tumors remain the primary indications, the convergence of epigenetic modulation with immunotherapy combinations represents the critical inflection point for clinical differentiation. Additionally, dual-target inhibitors and molecular glues are emerging as novel modalities to address refractory cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Pan-BET Inhibitor | AbbVie, Constellation, Roche | NUT Carcinoma, Solid Tumors | DSF/Tm Shift Assays (Need high-purity individual domains) |
| BD1/BD2 Selective Inhibitor | OncoEthix, Biogen, GSK | Inflammation, Oncology | Homolog Panel Screening (BRD2/BRD4 comparison required) |
| PROTAC Degrader | Arvinas, C4 Therapeutics, Kymera | Hematological Malignancies, Prostate Cancer | Ternary Complex Formation (Full-length protein essential) |
| Molecular Glue | Various Biotech | Refractory Cancers | Protein-Protein Interaction Assays (Mutant panel included) |
| Dual Target Inhibitor | Various Biotechs | Refractory Cancers | Kinetic Binding (Need Sequence Verified Recombinant Proteins) |
Related Targets for Synergistic Development
- BRD2: BET family sibling for selectivity counter-screening.
- BRD4: Primary BET target for comparative binding studies.
- MYC: Downstream effector for pathway validation studies.